Any stomach or gut side effect
56%
At every dose, vs 30% on placebo
Home Weight loss (GLP-1) Tirzepatide side effects
Tirzepatide's most common side effects are nausea, diarrhea, constipation and vomiting. In the Zepbound trials, nausea hit 25% to 29% of people on the drug against 8% on placebo, and most nausea, vomiting and diarrhea came while the dose was going up, then eased. Fewer than 7 in 100 stopped because of side effects.
Share of people who reported each side effect over up to 72 weeks in the two placebo-controlled Zepbound trials (SURMOUNT-1 and SURMOUNT-2). Each column is a fixed dose; placebo shows how often the same thing happened without the drug.
| Side effect | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 8% | |||
| Diarrhea | 8% | |||
| Constipation | 5% | |||
| Vomiting | 2% | |||
| Stomach pain | 5% | |||
| Indigestion (dyspepsia) | 4% | |||
| Injection site reactions | 2% | |||
| Tiredness | 3% | |||
| Allergic-type reactions | 3% | |||
| Burping | 1% | |||
| Hair loss | 1% | |||
| Acid reflux (GERD) | 2% |
Source: Zepbound prescribing information, Table 1 (adults with obesity or overweight, with or without type 2 diabetes; 958 on placebo, 630 on 5 mg, 948 on 10 mg, 941 on 15 mg). Bars are scaled for reading, not to 100%.
Any stomach or gut side effect
56%
At every dose, vs 30% on placebo
Stopped for any side effect
4.8-6.7%
5 mg to 15 mg, vs 3.4% on placebo
Stopped for a gut side effect
1.9-4.3%
5 mg to 15 mg, vs 0.5% on placebo
Each program is prescribed by a US-licensed clinician. Compounded tirzepatide is not FDA-approved; it is made by a compounding pharmacy.
Every program here is prescribed online by a US-licensed clinician, fills prescriptions through a licensed US pharmacy and lets you start without an office visit. Each card shows the price we read on the program's own site (or says when a program prices only after its intake) and what that price covers, and we keep the date of every read; some programs bill a membership and the medication separately, and the card says so. The label on each card says what that program stands out for. How we check prices and programs.
| Program | Support the program lists | Tirzepatide from | Visit |
|---|---|---|---|
| LevelsRx | Clinician review in about 24 hours; health coach, free dietitian consult and a 24/7 care team | $169/mo first month | Visit |
| BetterMe Rx | Provider review in about 24 hours; provider and supplies in the price | $159/mo 12-month plan | Visit |
| Maximus | Online evaluation in about 5 minutes; one flat rate at every dose | $99.99/mo 12-month plan | Visit |
| SHED | Coaching and check-ins built into the program | $239/mo 12-month plan | Visit |
| Direct Meds | Chart reviewed within 24 hours | $399/mo month to month | Visit |
| Gala | Video visits with a clinician and a health coach | $99/mo starting at | Visit |
| TrimRx | Free consultation and unlimited check-ins | $279/mo starting at | Visit |



Comes asVial

Comes asInjection or drops or troche

Comes asInjection or drops

Comes asInjection

The Zepbound label says most nausea, vomiting and diarrhea happened during dose escalation. In the trials, the dose was raised over up to 20 weeks.
The same label says these events "decreased over time" once people stayed on a dose. Most who stopped for side effects did so in the first few months.
Vomiting rose from 8% at 5 mg to 13% at 15 mg. Constipation was the exception: it was most common at 5 mg. The what to eat on a GLP-1 page covers the food side.
If a step is rough, the prescriber can wait longer before the next one. Every program on this page includes clinician follow-up.
Mounjaro is the same drug, tirzepatide, approved for type 2 diabetes. Its label pools placebo-controlled diabetes trials, and most rates are lower than in the Zepbound weight-loss trials. The trials differ (people, length, other medicines), so the two tables are not a head-to-head test.
| Side effect | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 4% | 12% | 15% | 18% |
| Diarrhea | 9% | 12% | 13% | 17% |
| Less appetite | 1% | 5% | 10% | 11% |
| Vomiting | 2% | 5% | 5% | 9% |
| Constipation | 1% | 6% | 6% | 7% |
| Indigestion (dyspepsia) | 3% | 8% | 8% | 5% |
| Stomach pain | 4% | 6% | 5% | 5% |
Source: Mounjaro prescribing information, Table 1 (adults with type 2 diabetes; 235 on placebo, 237 on 5 mg, 240 on 10 mg, 241 on 15 mg; low blood sugar not included in the table). Cost: Mounjaro cost.
These were rare in the Zepbound trials, and most are listed in the label's Warnings and Precautions (section 5); low blood pressure is from the adverse-reaction data (6.1). Message your clinician soon, or get urgent care, if you notice the signs.
| Problem | On tirzepatide | On placebo | Signs to act on |
|---|---|---|---|
| Gallbladder inflammation | 0.7% | 0.2% | Pain in the upper stomach, fever, yellow skin or eyes, clay-colored stools |
| Gallstones | 1.1% | 1% | Same as above |
| Low blood pressure | 1.6% | 0.1% | More likely with blood-pressure medicines, or with fluid loss from vomiting or diarrhea |
| Allergic reaction within a day | 2.1% | 0.4% | Swelling of the face or throat, trouble breathing, rash |
| Pancreatitis (confirmed) | 0.2% | 0.2% | Severe stomach pain that won't go away, with or without vomiting |
Source: Zepbound prescribing information, sections 5 and 6.1 (pool of the two weight-loss trials). The label also carries a boxed warning on thyroid C-cell tumors seen in rodents: a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath needs a call. Your clinician sets your dose.
Nausea, diarrhea, constipation and vomiting. In the Zepbound weight-loss trials, nausea was reported by 25% to 29% of people on tirzepatide, depending on the dose, against 8% on placebo. Stomach pain, indigestion, tiredness, burping, hair loss and reflux were each reported by 4% to 10%.
Some do. Vomiting rose from 8% at 5 mg to 13% at 15 mg, and diarrhea from 19% to 23%. Constipation went the other way (17% at 5 mg, 11% at 15 mg). The share of people who stopped for any side effect rose from 4.8% to 6.7% (3.4% on placebo).
The Zepbound label says most nausea, vomiting and diarrhea happened while the dose was being raised and decreased over time. In the trials the dose was raised over up to 20 weeks, then held. Your clinician can slow the next step if a dose is hard.
They are the same medicine, tirzepatide. The Mounjaro numbers come from trials in people with type 2 diabetes and are lower on most lines (nausea 12% to 18%). The trials enrolled different people, so the two sets of rates cannot be compared directly.
Hair loss was reported by 4% to 5% on Zepbound and 1% on placebo. The label links it to weight reduction and notes it was more common in women (7.1%) than men (0.5%). See our page on hair loss on a GLP-1.
Compounded tirzepatide is not FDA-approved and was not tested in these trials, so the rates on this page come from Zepbound, not from compounded products. Ask your clinician or pharmacy about anything on your prescription that is unclear.
Gallbladder problems were uncommon but more frequent than on placebo: gallbladder inflammation in 0.7% vs 0.2%. Gallstones were about even (1.1% vs 1%). Pain in the upper stomach with fever, or yellow skin or eyes, needs a call to your clinician.
General information, not medical advice. Your clinician decides whether tirzepatide is right for you.
Related: hair loss on a GLP-1, compounded semaglutide side effects, semaglutide vs. tirzepatide, tirzepatide price.
Exclusive discounts, price-drop alerts and Black Friday deals before everyone else. Pick what your card covers.
Some deals and approvals apply only to certain ages, or only to men or women.
Unsubscribe in one click.
Popular with members right now: